Cargando…

Cellular Signaling Pathway Alterations and Potential Targeted Therapies for Medullary Thyroid Carcinoma

Parafollicular C-cell-derived medullary thyroid cancer (MTC) comprises 3% to 4% of all thyroid cancers. While cytotoxic treatments have been shown to have limited efficacy, targeted molecular therapies that inhibit rearranged during transfection (RET) and other tyrosine kinase receptors that are mai...

Descripción completa

Detalles Bibliográficos
Autores principales: Giunti, Serena, Antonelli, Alessandro, Amorosi, Andrea, Santarpia, Libero
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3594951/
https://www.ncbi.nlm.nih.gov/pubmed/23509459
http://dx.doi.org/10.1155/2013/803171
_version_ 1782262366933614592
author Giunti, Serena
Antonelli, Alessandro
Amorosi, Andrea
Santarpia, Libero
author_facet Giunti, Serena
Antonelli, Alessandro
Amorosi, Andrea
Santarpia, Libero
author_sort Giunti, Serena
collection PubMed
description Parafollicular C-cell-derived medullary thyroid cancer (MTC) comprises 3% to 4% of all thyroid cancers. While cytotoxic treatments have been shown to have limited efficacy, targeted molecular therapies that inhibit rearranged during transfection (RET) and other tyrosine kinase receptors that are mainly involved in angiogenesis have shown great promise in the treatment of metastatic or locally advanced MTC. Multi-tyrosine kinase inhibitors such as vandetanib, which is already approved for the treatment of progressive MTC, and cabozantinib have shown distinct advantages with regard to rates of disease response and control. However, these types of tyrosine kinase inhibitor compounds are able to concurrently block several types of targets, which limits the understanding of RET as a specific target. Moreover, important resistances to tyrosine kinase inhibitors can occur, which limit the long-term efficacy of these treatments. Deregulated cellular signaling pathways and genetic alterations in MTC, particularly the activation of the RAS/mammalian target of rapamycin (mTOR) cascades and RET crosstalk signaling, are now emerging as novel and potentially promising therapeutic treatments for aggressive MTC.
format Online
Article
Text
id pubmed-3594951
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-35949512013-03-18 Cellular Signaling Pathway Alterations and Potential Targeted Therapies for Medullary Thyroid Carcinoma Giunti, Serena Antonelli, Alessandro Amorosi, Andrea Santarpia, Libero Int J Endocrinol Review Article Parafollicular C-cell-derived medullary thyroid cancer (MTC) comprises 3% to 4% of all thyroid cancers. While cytotoxic treatments have been shown to have limited efficacy, targeted molecular therapies that inhibit rearranged during transfection (RET) and other tyrosine kinase receptors that are mainly involved in angiogenesis have shown great promise in the treatment of metastatic or locally advanced MTC. Multi-tyrosine kinase inhibitors such as vandetanib, which is already approved for the treatment of progressive MTC, and cabozantinib have shown distinct advantages with regard to rates of disease response and control. However, these types of tyrosine kinase inhibitor compounds are able to concurrently block several types of targets, which limits the understanding of RET as a specific target. Moreover, important resistances to tyrosine kinase inhibitors can occur, which limit the long-term efficacy of these treatments. Deregulated cellular signaling pathways and genetic alterations in MTC, particularly the activation of the RAS/mammalian target of rapamycin (mTOR) cascades and RET crosstalk signaling, are now emerging as novel and potentially promising therapeutic treatments for aggressive MTC. Hindawi Publishing Corporation 2013 2013-02-21 /pmc/articles/PMC3594951/ /pubmed/23509459 http://dx.doi.org/10.1155/2013/803171 Text en Copyright © 2013 Serena Giunti et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Giunti, Serena
Antonelli, Alessandro
Amorosi, Andrea
Santarpia, Libero
Cellular Signaling Pathway Alterations and Potential Targeted Therapies for Medullary Thyroid Carcinoma
title Cellular Signaling Pathway Alterations and Potential Targeted Therapies for Medullary Thyroid Carcinoma
title_full Cellular Signaling Pathway Alterations and Potential Targeted Therapies for Medullary Thyroid Carcinoma
title_fullStr Cellular Signaling Pathway Alterations and Potential Targeted Therapies for Medullary Thyroid Carcinoma
title_full_unstemmed Cellular Signaling Pathway Alterations and Potential Targeted Therapies for Medullary Thyroid Carcinoma
title_short Cellular Signaling Pathway Alterations and Potential Targeted Therapies for Medullary Thyroid Carcinoma
title_sort cellular signaling pathway alterations and potential targeted therapies for medullary thyroid carcinoma
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3594951/
https://www.ncbi.nlm.nih.gov/pubmed/23509459
http://dx.doi.org/10.1155/2013/803171
work_keys_str_mv AT giuntiserena cellularsignalingpathwayalterationsandpotentialtargetedtherapiesformedullarythyroidcarcinoma
AT antonellialessandro cellularsignalingpathwayalterationsandpotentialtargetedtherapiesformedullarythyroidcarcinoma
AT amorosiandrea cellularsignalingpathwayalterationsandpotentialtargetedtherapiesformedullarythyroidcarcinoma
AT santarpialibero cellularsignalingpathwayalterationsandpotentialtargetedtherapiesformedullarythyroidcarcinoma